ketoconazole has been researched along with ritonavir in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.00) | 18.2507 |
| 2000's | 20 (33.33) | 29.6817 |
| 2010's | 34 (56.67) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Atkinson, K; Chang, G; Di, L; Filipski, KJ; Kalgutkar, AS; Keefer, C; Lin, J; Litchfield, J; Mongillo, RK; Orozco, CC; Riccardi, K; Ryu, S; Scott, D; Tess, D | 1 |
| Norman, BH | 1 |
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Remmel, RP; Tracy, TS; Zhou, J | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Aeri, K; Chang, M; Kim, HJ; Koh, JS; Lee, SH | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Andréola, ML; Bailly, F; Calmels, C; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andréola, ML; Bailly, F; Billamboz, M; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V | 1 |
| Gangl, E; Gerber, N; Iatsimirskaia, E; Koudriakova, T; Marinina, J; Orza, D; Storozhuk, E; Utkin, I; Vouros, P | 1 |
| Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Zalma, A | 1 |
| Daily, JP; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Hoffman, JL; Mertzanis, P; Shader, RI; von Moltke, LL | 1 |
| Duan, SX; Durol, AL; Greenblatt, DJ; von Moltke, LL | 1 |
| Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Cameron, DW; Gallicano, K; Khaliq, Y; Kravcik, S; Venance, S | 1 |
| Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H | 1 |
| Greenblatt, DJ; Perloff, MD; Von Moltke, LL | 1 |
| Back, DJ; Boffito, M; Bonora, S; Dal Conte, I; Di Perri, G; Hoggard, PG; Khoo, S; Sales, P; Sinicco, A | 1 |
| Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G | 1 |
| Amantea, MA; Nickens, DJ; Raber, SR; Reynolds, RR; Sarapa, N | 1 |
| Autar, RS; Burger, DM; Cooper, DA; Hassink, E; Hill, A; Kimenai, E; Lange, JM; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sutthichom, D; Wit, FW | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T | 1 |
| Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H | 1 |
| Bour, F; Kaeser, B; Schmitt, C; Zandt, H; Zhang, X; Zwanziger, E | 1 |
| de Greef-van der Sandt, IC; Freidig, AP; Nijmeijer, S; Treijtel, N; van Eijkeren, JC | 1 |
| Poulos, TL; Sevrioukova, IF | 1 |
| Cui, SL; Deng, JT; Kong, WL; Li, H; Tian, XT; Wen, YY; Xie, L; Zhuang, XM | 1 |
| Louisa, M; Setiabudy, R; Soetikno, V; Suyatna, FD | 1 |
| Bellavance, E; Bourg, S; Duan, J; Garneau, M; Ribadeneira, MD; Rioux, N | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Hee, KH; Lee, LS; Yao, Z | 1 |
| Brennan, BJ; Chang, L; Chung, D; Morcos, PN; Navarro, M; Smith, PF; Tran, JQ | 1 |
| Chang, CY; Deeken, JF; Desai, N; Johnson, MD; Rudek, MA; Steadman, K | 1 |
| Beumer, JH; Christner, SM; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R | 1 |
| Greenblatt, DJ; Harmatz, JS | 1 |
| Beumer, JH; Christner, SM; Kiesel, BF; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R | 1 |
| Aburub, A; Chen, X; Fadda, HM; Mishra, D; Pinal, R | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
| Buckley, DB; Isringhausen, CD; Ogilvie, BW; Vermeer, LM | 1 |
| Daali, Y; Desmeules, JA; Fontana, P; Marsousi, N; Reny, JL; Rudaz, S; Samer, CF | 1 |
| Ge, W; Jiang, Q; Xu, R | 1 |
| Anderson, MS; Fan, L; Iwamoto, M; Khalilieh, SG; Laethem, T; Rasmussen, S; Sanchez, RI; Sura, M; van Bortel, L; van Lancker, G; Yee, KL | 1 |
| Britt, RD; Chuo, SW; Goodin, DB; Liou, SH; Poulos, TL; Sevrioukova, IF; Wang, LP | 1 |
| Arora, S; Gardner, I; Jamei, M; Kilford, PJ; Pansari, A; Turner, DB | 1 |
3 review(s) available for ketoconazole and ritonavir
| Article | Year |
|---|---|
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Topics: Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Interactions; Humans; Ketoconazole; Midazolam; Ritonavir; United States; United States Food and Drug Administration | 2015 |
9 trial(s) available for ketoconazole and ritonavir
| Article | Year |
|---|---|
Alprazolam-ritonavir interaction: implications for product labeling.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Labeling; Female; HIV Protease Inhibitors; Humans; Hydroxylation; Ketoconazole; Male; Metabolic Clearance Rate; Microsomes, Liver; Oxidoreductases, N-Demethylating; Protein Isoforms; Ritonavir | 2000 |
Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
Topics: Adult; Antifungal Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Longitudinal Studies; Male; Middle Aged; Ritonavir; Saquinavir | 2000 |
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Topics: Adult; Aza Compounds; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drug Therapy, Combination; Electrocardiography; Female; Fluoroquinolones; Heart Rate; HIV Protease Inhibitors; Humans; Imidazoles; Ketoconazole; Liver; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Reference Values; Reproducibility of Results; Research Design; Reverse Transcriptase Inhibitors; Ritonavir; Sulfur Compounds; Treatment Outcome | 2008 |
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Male; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2007 |
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome | 2008 |
Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
Topics: Adult; Aged; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Ritonavir; Saquinavir; Young Adult | 2009 |
Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Calibration; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Freezing; Glucuronosyltransferase; Healthy Volunteers; Humans; Ketoconazole; Midazolam; Particle Size; Pyrrolidinones; Quality Control; Raltegravir Potassium; Reproducibility of Results; Rifampin; Ritonavir; Solid Phase Extraction; Tandem Mass Spectrometry; Xenobiotics | 2014 |
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Topics: Adult; Area Under Curve; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Isoindoles; Ketoconazole; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ritonavir; Sulfonamides | 2014 |
48 other study(ies) available for ketoconazole and ritonavir
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Structural attributes influencing unbound tissue distribution.
Topics: Animals; Dose-Response Relationship, Drug; Infusions, Intravenous; Male; Models, Molecular; Molecular Structure; Organic Chemicals; Pharmaceutical Preparations; Rats; Rats, Wistar; Structure-Activity Relationship; Tissue Distribution | 2020 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
Topics: Bilirubin; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Humans; Pharmaceutical Preparations; Recombinant Proteins; Substrate Specificity | 2011 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.
Topics: Alkyl and Aryl Transferases; Animals; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Microsomes, Liver; Piperazines | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
Topics: Aryl Hydrocarbon Hydroxylases; Cell Line, Tumor; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Resistance, Viral; HIV Integrase Inhibitors; HIV-1; Humans; Isoquinolines; Molecular Docking Simulation; Mutation; Structure-Activity Relationship | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
Topics: Alkylation; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Integrase Inhibitors; Humans; Isoquinolines; Structure-Activity Relationship | 2016 |
Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Topics: Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Mucosa; Ketoconazole; Kinetics; Microsomes; Mixed Function Oxygenases; Ritonavir | 1998 |
Ketoconazole may improve PI penetration.
Topics: Blood-Brain Barrier; Drug Synergism; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Ketoconazole; Ritonavir; Saquinavir; Viral Load | 1999 |
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Topics: Antidepressive Agents, Second-Generation; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Microsomes, Liver; Nelfinavir; Oxidoreductases, N-Demethylating; Piperazines; Ritonavir; Saquinavir; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Trazodone | 2000 |
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Furans; Humans; Hydroxylation; Ketoconazole; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides; Triazolam | 2000 |
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Topics: Anti-Anxiety Agents; Benzoflavones; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Flunitrazepam; Humans; Hydroxylation; Isoenzymes; Ketoconazole; Kinetics; Methylation; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Quinidine; Ritonavir; Sulfaphenazole; Transfection | 2001 |
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Female; Gene Expression; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Topics: Algorithms; Animals; Anti-Anxiety Agents; Antibodies, Blocking; Biotransformation; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; In Vitro Techniques; Intestinal Mucosa; Isoenzymes; Ketoconazole; Kinetics; Mice; Mice, Inbred ICR; Microsomes; Microsomes, Liver; Midazolam; Organ Specificity; Ritonavir; Troleandomycin | 2003 |
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.
Topics: Antifungal Agents; Drug Combinations; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Pyrimidinones; Ritonavir | 2003 |
Maraviroc: in vitro assessment of drug-drug interaction potential.
Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles | 2008 |
Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.
Topics: Animals; Biological Transport, Active; Cell Culture Techniques; Cell Survival; Cells, Cultured; Cyclosporine; Cyclosporins; Dose-Response Relationship, Drug; Hepatocytes; HIV Protease Inhibitors; Ketoconazole; Male; Metabolic Clearance Rate; Microsomes, Liver; Rats; Rats, Wistar; Ritonavir; Saquinavir | 2009 |
Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Topics: Binding Sites; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Heme; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Ketoconazole; Kinetics; Ligands; Macromolecular Substances; Models, Molecular; Molecular Structure; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Ritonavir; Spectrophotometry | 2010 |
[Metabolism of 3-cyanomethyl-4-methyl-DCK, a new anti-HIV candidate, in human intestinal microsomes].
Topics: Anti-HIV Agents; Biological Availability; Bridged Bicyclo Compounds, Heterocyclic; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Intestinal Mucosa; Ketoconazole; Metabolic Clearance Rate; Microsomes; Ritonavir; Troleandomycin | 2010 |
Co-administration of ritonavir and primaquine decreases plasma concentration of primaquine: single- and multiple-dose study in the rats.
Topics: Animals; Antifungal Agents; Antimalarials; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Ketoconazole; Male; Primaquine; Random Allocation; Rats; Rats, Sprague-Dawley; Ritonavir | 2012 |
Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
Topics: Animals; Buspirone; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Male; Microsomes, Liver; Rats; Rats, Wistar; Ritonavir; Verapamil | 2013 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
Topics: Alkynes; Animals; Antineoplastic Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Docetaxel; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; HIV Protease Inhibitors; Ketoconazole; Liver; Male; Mice; Reverse Transcriptase Inhibitors; Ritonavir; Taxoids | 2014 |
Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antifungal Agents; Antineoplastic Agents; Area Under Curve; Benzoxazines; Cells, Cultured; Cyclopropanes; Drug Interactions; Female; Half-Life; Hepatocytes; Humans; Ketoconazole; Male; Middle Aged; Pyrimidines; Rifampin; Ritonavir; Young Adult | 2014 |
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Hepatocytes; Humans; Imatinib Mesylate; Ketoconazole; Male; Middle Aged; Primary Cell Culture; Rifampin; Ritonavir; Young Adult | 2015 |
Cosolvency approach for assessing the solubility of drugs in poly(vinylpyrrolidone).
Topics: Griseofulvin; Itraconazole; Ketoconazole; Models, Chemical; Polymers; Povidone; Ritonavir; Solubility; Solvents; X-Ray Diffraction | 2015 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Topics: Biological Transport; Cell Line; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HEK293 Cells; Humans; Itraconazole; Ketoconazole; Membrane Transport Proteins; Ritonavir | 2016 |
Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach.
Topics: Adenosine; Adult; Area Under Curve; Blood Platelets; Cytochrome P-450 CYP3A Inhibitors; Half-Life; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Platelet Aggregation Inhibitors; Prospective Studies; Ritonavir; Ticagrelor; Young Adult | 2016 |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Computer Simulation; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Factor Xa Inhibitors; Humans; Ketoconazole; Liver Diseases; Male; Models, Biological; Renal Insufficiency; Ritonavir; Rivaroxaban | 2018 |
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2019 |
Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution.
Topics: Cytochrome P-450 CYP3A; Electron Spin Resonance Spectroscopy; Humans; Ketoconazole; Ligands; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Protein Structure, Secondary; Ritonavir | 2019 |
A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; Ketoconazole; Models, Biological; Ritonavir | 2022 |